Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
189.78 USD | +0.00% |
|
-0.60% | +6.70% |
01:46pm | Major deals involving U.S. drugmakers and biotechs over the past decade | RE |
07:01am | Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy | RE |
Business description: AbbVie Inc.
Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).
Number of employees: 55,000
Sales by Activity: AbbVie Inc.
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Innovative Medicines and Therapies | 45.8B | 56.2B | 58.05B | 54.32B | 56.33B |
Geographical breakdown of sales: AbbVie Inc.
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States | 34.88B | 43.51B | 45.71B | 41.88B | 43.03B |
ALL Other Countries | 3.98B | 4.76B | 4.84B | 5.04B | 5.45B |
Germany | 1.05B | 1.22B | 1.34B | 1.27B | 1.46B |
Japan | 1.2B | 1.09B | 956M | 1.01B | 1.12B |
Canada | 1.16B | 1.4B | 1.16B | 1.08B | 1.09B |
China | 471M | 857M | 912M | 950M | 917M |
France | 797M | 936M | 787M | 780M | 776M |
Spain | 453M | 519M | 506M | 501M | 528M |
United Kingdom | 509M | 497M | 462M | 417M | 522M |
Italy | 379M | 506M | 444M | 484M | 511M |
Brazil | 406M | 368M | 430M | 439M | 464M |
Australia | 527M | 533M | 508M | 472M | 463M |
Executive Committee: AbbVie Inc.
Manager | Title | Age | Since |
---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 2024-06-30 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 2022-06-22 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 2002-12-31 |
Chief Operating Officer | 61 | 2023-06-30 | |
Liz Shea
IRC | Investor Relations Contact | - | 2012-12-31 |
Composition of the Board of Directors: AbbVie Inc.
Director | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 2012-12-31 |
William Burnside
BRD | Director/Board Member | 73 | 2012-12-31 |
Edward Rapp
BRD | Director/Board Member | 67 | 2012-12-31 |
Robert Michael
CHM | Chairman | 54 | 2025-06-30 |
Rebecca Roberts
BRD | Director/Board Member | 72 | 2017-12-31 |
Thomas Freyman
BRD | Director/Board Member | 70 | 2020-05-07 |
Robert Alpern
BRD | Director/Board Member | 74 | 2012-12-31 |
Brett Hart
BRD | Director/Board Member | 55 | 2015-12-31 |
Melody Meyer
BRD | Director/Board Member | 67 | 2016-12-31 |
Director/Board Member | 71 | 2012-12-31 |
Holdings: AbbVie Inc.
Name | Equities | % | Valuation |
---|---|---|---|
4,347,826 | 9.5% | 2,956,522 $ | |
1,855,871 | 4.45% | 723,790 $ |
Company details: AbbVie Inc.

Group companies: AbbVie Inc.
Name | Category and Sector |
---|---|
AbbVie Biopharmaceuticals GmbH Taiwan Branch |
Pharmaceuticals: Major
|
AbbVie SAS
![]() AbbVie SAS Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., AbbVie SAS is a Colombian company that develops drugs and pharmaceutical products. The company is based in Bogota, Colombia. The company was founded in 2012. The CEO is Eduardo Leyva. |
Pharmaceuticals: Major
|
AbbVie Logistics BV
![]() AbbVie Logistics BV Medical DistributorsDistribution Services Part of AbbVie, Inc., AbbVie Logistics BV is a wholesaler of pharmaceutical products. The company is based in Zwolle, Netherlands. |
Medical Distributors
|
AbbVie Finance BV | |
Pharmacyclics Switzerland GmbH
![]() Pharmacyclics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., Pharmacyclics Switzerland GmbH is a Swiss company that manufactures pharmaceutical products. The company is located in Switzerland. |
Pharmaceuticals: Major
|
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+0.00% | -0.60% | +12.83% | +23.74% | 335B | ||
+0.98% | +0.82% | -15.75% | +137.31% | 698B | ||
-0.14% | -0.05% | +5.74% | -12.82% | 375B | ||
-1.53% | +0.35% | -54.14% | +9.26% | 313B | ||
+0.89% | -0.04% | +6.30% | -20.36% | 259B | ||
-0.16% | -0.89% | +0.47% | +17.53% | 240B | ||
+0.21% | -0.27% | -13.25% | -7.10% | 217B | ||
+3.05% | +1.59% | -33.59% | -11.24% | 204B | ||
-0.67% | -0.70% | -6.69% | +18.97% | 160B | ||
-0.72% | +0.28% | -8.41% | -51.99% | 146B | ||
Average | +0.16% | +0.74% | -10.65% | +10.33% | 294.8B | |
Weighted average by Cap. | +0.25% | +0.50% | -10.79% | +31.36% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
- Company AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions